Boryung Corporation (KRX:003850)
South Korea
· Delayed Price · Currency is KRW 9,380.00
-20.00 (-0.21%)
At close: Mar 24, 2025, 3:30 PM KST
Boryung Revenue
In the year 2024, Boryung had annual revenue of 1.02T KRW with 18.32% growth. Boryung had revenue of 256.91B in the quarter ending December 31, 2024, with 11.10% growth.
Revenue
1,017.11B
Revenue Growth
+18.32%
P/S Ratio
0.61
Revenue / Employee
663.47M
Employees
1,533
Market Cap
758.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,017.11B | 157.48B | 18.32% |
| Dec 31, 2023 | 859.63B | 99.15B | 13.04% |
| Dec 31, 2022 | 760.48B | 133.20B | 21.23% |
| Dec 31, 2021 | 627.28B | 65.41B | 11.64% |
| Dec 31, 2020 | 561.87B | 37.60B | 7.17% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2012 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 51.92B |
| Sam Chun Dang Pharm. | 210.92B |
| PharmaResearch | 350.12B |